ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » California » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in California

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
SARABJIT SINGH MD

Cardiovascular Disease

6,229

$302K

886
763 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 28%

$49
Average prescription price

Avg: $67

JOHN TZENG M.D., PH.D.

Cardiovascular Disease

17,845

$1.07M

873
844 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

41%
prescriptions for brand name drugs

Avg: 28%

$60
Average prescription price

Avg: $67

SIVA ARUNASALAM

Cardiovascular Disease

10,589

$1.22M

863
667 are 65+

4%
patients receiving schedule two controlled substances

Avg: 0%

20%
patients receiving schedule three controlled substances

Avg: 2%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 28%

$115
Average prescription price

Avg: $67

ASHIT JAIN M.D.

Cardiovascular Disease

9,628

$636K

860
749 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

11%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 28%

$66
Average prescription price

Avg: $67

RANA BAHL MD

Cardiovascular Disease

9,518

$322K

856
698 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 28%

$34
Average prescription price

Avg: $67

MICHAEL KRUEGER DO

Cardiovascular Disease

6,487

$443K

848
708 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$68
Average prescription price

Avg: $67

LARRY BERTE M.D

Cardiovascular Disease

8,488

$432K

845
778 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 28%

$51
Average prescription price

Avg: $67

ADNAN NABER M.D.

Cardiovascular Disease

4,946

$409K

833
781 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 28%

$83
Average prescription price

Avg: $67

BENJAMIN ROSIN M.D.

Cardiovascular Disease

11,043

$768K

825
802 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

1%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 28%

$70
Average prescription price

Avg: $67

ALVIN CACHO M.D.

Cardiovascular Disease

11,362

$714K

822
702 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 28%

$63
Average prescription price

Avg: $67

B CHANDRAMOULI MD

Cardiovascular Disease

9,014

$477K

816
721 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 28%

$53
Average prescription price

Avg: $67

ALBERT SHARF MD

Cardiovascular Disease

16,547

$805K

807
683 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 28%

$49
Average prescription price

Avg: $67

DALPINDER SANDHU MD

Cardiovascular Disease

8,291

$569K

806
725 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 28%

$69
Average prescription price

Avg: $67

DONALD GREGORY M.D.

Cardiovascular Disease

8,107

$412K

794
741 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 28%

$51
Average prescription price

Avg: $67

ERIC SONTZ M.D.

Cardiovascular Disease

5,431

$505K

789
748 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$93
Average prescription price

Avg: $67

PRAMOD MULTANI MD

Cardiovascular Disease

21,714

$1.21M

781
673 are 65+

3%
patients receiving schedule two controlled substances

Avg: 0%

16%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 28%

$56
Average prescription price

Avg: $67

HUGO RIFFEL DALINGER MD

Cardiovascular Disease

11,987

$910K

775
740 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

42%
prescriptions for brand name drugs

Avg: 28%

$76
Average prescription price

Avg: $67

BRIJESH BHAMBI M.D.

Cardiovascular Disease

7,202

$587K

773
661 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 28%

$81
Average prescription price

Avg: $67

TOM YEH M.D.

Cardiovascular Disease

28,209

$1.52M

772
749 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$54
Average prescription price

Avg: $67

RAMIN MANSHADI MD

Cardiovascular Disease

8,759

$1.01M

765
554 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 28%

$115
Average prescription price

Avg: $67

KENT WONG MD

Cardiovascular Disease

5,798

$337K

764
678 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

7%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 28%

$58
Average prescription price

Avg: $67

VACHASPATHI PALAKODETI MD

Cardiovascular Disease

4,129

$262K

764
674 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$63
Average prescription price

Avg: $67

RAVI GUPTA MD

Cardiovascular Disease

8,658

$450K

764
691 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$52
Average prescription price

Avg: $67

EDGAR ALEMAN MD

Cardiovascular Disease

13,340

$866K

763
738 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 28%

$65
Average prescription price

Avg: $67

PETER FUNG MD

Cardiovascular Disease

10,952

$653K

745
716 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 2%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 28%

$60
Average prescription price

Avg: $67

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank